FDA lifts pause on Johnson & Johnson vaccine; Oregon use pending Western States’ review

Today, a federal vaccine safety review panel recommended lifting the pause on the Johnson & Johnson COVID-19 vaccine for people 18 and older. Based on the panel’s recommendation, the U.S. Food and Drug Administration (FDA) lifted the pause and added a warning about the rare side effects of blood clots in women under the age of 50.

The Western States Scientific Safety Review Workgroup, composed of public health experts from Oregon, California, Washington and Nevada, will now convene to review the FDA’s decision to lift the pause. Once that review is completed, OHA will share those recommendations to clinicians and vaccine providers on plans for the resumption of the vaccine’s use and distribution in Oregon.

To learn more, read OHA’s full press release here.